Q-omics provides the consensus-scored OR52E6 profile across patient tissues and cancer cell-line models. OR52E6 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OR52E6 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, OR52E6 RNA expression shows 11,654 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, BRCA, and THYM as cancer lineages where OR52E6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR52E6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR52E6 survival associations across molecular data types. OR52E6 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR52E6 RNA expression–survival associations across cancer types. High OR52E6 expression shows unfavorable associations in ACC, BRCA, LIHC, THCA, MESO and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OR52E6 RNA expression.
This table summarizes OR52E6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR52E6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR52E6 shows lower tumor expression in KIRC and higher tumor expression in BRCA, LIHC, STAD and LUSC. The BRCA box plot shows higher OR52E6 RNA expression in tumor versus normal tissue (log2 FC = +0.056, t-test p = .003).
This table shows molecular features associated with OR52E6 in patient tissues and cancer cell lines. In patient samples, OR52E6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR52E6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
